Date: {{$ActivityAssignDate}}

Dear Dr. {{ $doctorName }},

Subject: : To participate in a cross-sectional survey on Demographics & Management Practices in Acid Peptic Disease

Acid peptic diseases result from distinctive but overlapping pathogenic mechanisms that typically involve acid effects on diminished mucosal defense. Conditions such as acid reflux, damage to the esophageal mucosa, and also potentially cause laryngeal tissue injury with subsequent development of pulmonary symptoms. A peptic ulcer is histologically defined as a mucosal defect that extends to or beyond the muscularis mucosa, with mucosal damage due to pepsin and gastric acid secretion. Most ulcers occur in the stomach and proximal duodenum, while less commonly in the lower esophagus, the distal duodenum, or the jejunum.

Acid-related disorders influence the quality of life and productivity of afflicted patients and are common and important causes of morbidity and mortality. The prevalence of GERD in India ranges from 7.6% to 30%, being < 10% in most population studies, and higher in cohort studies.

Peptic acid diseases arise from distinctive but overlapping pathogenic mechanisms but ultimately have a common mechanism of tissue injury from acid. Gastric hydrochloric acid secretion is modulated by neural and hormonal stimulation of receptors on the basolateral membrane, as well as by activation of enzymes located on the surface of parietal cells. Modern therapy is aimed at these physiological targets.

The goals of therapy include relief of symptoms, enhancement of ulcer healing in the affected mucosa (esophagus, stomach, and duodenum), and prevention of recurrence. Milestones in the treatment of these diseases have included:

• The discovery of the histamine H2-receptor and its functional antagonists


• Identification of the H+ K+-adenosine triphosphatase (H+K+-ATPase) enzyme and the development of proton-pump inhibitors (PPIs)


• Confirmation of H. pylori as a peptic ulcer causative agent with the subsequent development of effective antibiotic eradication regimens

This survey will help

• Understand the management practices of physicians treating acid peptic disorders, with a focus on PPI therapy


• Assess the trends in PPI use, particularly in patients with comorbidities such as cardiovascular diseases, diabetes, or those on antiplatelet and NSAID therapy.


• Evaluate the efficacy of various drugs/combinations in the treatment of GERD and APD.


• Explore the impact of demographic factors such as age, gender, and geographic region on treatment decisions and physician prescribing patterns.


• Identify any gaps in knowledge or areas for improvement in the management of acid peptic disorders.

If you agree to participate, you must provide an assessment response to the standard questionnaire form. A link will be provided for the same on your registered email address.

We trust you, and we are partners in safe and effective drug therapy. In that spirit, we hope you will consent to participate in this survey.